Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenji Hashimoto

Showing results (61-70 of 861) with videos related to

Pageof 87
Sort By:
Frontiers in Pharmacology|November 3, 2018
Essential Role of Keap1-Nrf2 Signaling in Mood Disorders: Overview and Future PerspectiveKenji Hashimoto
Recent Patents on CNS Drug Discovery|January 29, 2008
Glycine transporter inhibitors as therapeutic agents for schizophreniaKenji Hashimoto
Schizophrenia Research|May 10, 2014
Abnormalities of the glutamine-glutamate-GABA cycle in the schizophrenia brainKenji Hashimoto
The British Journal of Psychiatry : the Journal of Mental Science|July 22, 2025
Host microbiota in clozapine-induced ileus and pneumonia among people with schizophreniaKenji Hashimoto
European Archives of Psychiatry and Clinical Neuroscience|February 14, 2023
Arketamine for cognitive impairment in psychiatric disordersKenji Hashimoto
Discover Mental Health|March 27, 2023
Overview of the potential use of fluvoxamine for COVID-19 and long COVIDKenji Hashimoto
Brain, Behavior, & Immunity - Health|March 25, 2024
Viewpoints Sigma-1 receptor agonist fluvoxamine for multiple sclerosisKenji Hashimoto
British Journal of Pharmacology|April 21, 2026
Reconsidering the gamma-delta shift as a biomarker of antidepressant effects of ketamine enantiomersKenji Hashimoto
European Archives of Psychiatry and Clinical Neuroscience|January 12, 2021
Neural rhythm in the retrosplenial cortex during ketamine-induced dissociationKenji Hashimoto
Military Medical Research|October 2, 2025
Substantia nigra-related gene polymorphisms associated with acute antipsychotic-induced movement disordersKenji Hashimoto
Pageof 87

Showing results (61-70 of 861) with videos related to

Sort By:
Pageof 87
Frontiers in Pharmacology|November 3, 2018
Essential Role of Keap1-Nrf2 Signaling in Mood Disorders: Overview and Future PerspectiveKenji Hashimoto
Recent Patents on CNS Drug Discovery|January 29, 2008
Glycine transporter inhibitors as therapeutic agents for schizophreniaKenji Hashimoto
Schizophrenia Research|May 10, 2014
Abnormalities of the glutamine-glutamate-GABA cycle in the schizophrenia brainKenji Hashimoto
The British Journal of Psychiatry : the Journal of Mental Science|July 22, 2025
Host microbiota in clozapine-induced ileus and pneumonia among people with schizophreniaKenji Hashimoto
European Archives of Psychiatry and Clinical Neuroscience|February 14, 2023
Arketamine for cognitive impairment in psychiatric disordersKenji Hashimoto
Discover Mental Health|March 27, 2023
Overview of the potential use of fluvoxamine for COVID-19 and long COVIDKenji Hashimoto
Brain, Behavior, & Immunity - Health|March 25, 2024
Viewpoints Sigma-1 receptor agonist fluvoxamine for multiple sclerosisKenji Hashimoto
British Journal of Pharmacology|April 21, 2026
Reconsidering the gamma-delta shift as a biomarker of antidepressant effects of ketamine enantiomersKenji Hashimoto
European Archives of Psychiatry and Clinical Neuroscience|January 12, 2021
Neural rhythm in the retrosplenial cortex during ketamine-induced dissociationKenji Hashimoto
Military Medical Research|October 2, 2025
Substantia nigra-related gene polymorphisms associated with acute antipsychotic-induced movement disordersKenji Hashimoto
Pageof 87